Method of predicting acute appendicitis
AssigneeChildren's Medical Center Corporation
InventorsAlex Kentsis, Hanno Steen, Richard Bachur
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
Claims20
A device comprising:
- a. at least one protein-binding agent which specifically binds to at least one appendicitis biomarker protein selected from the group of:
- leucine α-2 glycoprotein (LRG), mannan-binding lectin serine protease 2 (MASP2), α-1-acid glycoprotein 1 (ORM);
- and
- b. at least one solid support for the at least one protein binding-agent in (a), wherein the protein-binding agent is deposited on the solid support.
A method to identify the likelihood of a subject having acute appendicitis comprising:
- a. measuring the level of at least one biomarker protein selected from the group listed in Table 1 in a urine sample from the human subject;
- b. comparing the level of the at least one biomarker protein measured in step (a) to a reference level for the measured biomarker;
- wherein the level of a measured biomarker is at least 2-fold increased than the reference level for the biomarker indicates that the subject is likely to have acute appendicitis.
Dependencies are inferred from the claim text.